A Safety, Pilot Pharmacokinetics and Neurocognitive Study of AS-101 in Combination With Zidovudine in AIDS/ARC Patients
Not Applicable
Completed
- Conditions
- HIV Infections
- Registration Number
- NCT00002013
- Lead Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
- Brief Summary
To evaluate safety, pharmacokinetics, immunologic parameters and neurocognitive data for three dosages of AS-101 in combination with zidovudine (AZT) in patients with AIDS or AIDS related complex (ARC).
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What is the mechanism of action of AS-101 in modulating immune response in HIV Infections?
How does the combination of AS-101 and Zidovudine compare to standard antiretroviral therapies in AIDS patients?
Are there specific biomarkers associated with improved neurocognitive outcomes when using AS-101 in HIV treatment?
What are the potential adverse events and safety concerns of AS-101 combined with Zidovudine in AIDS/ARC patients?
What other compounds or combination therapies have shown promise in targeting neurocognitive decline in HIV Infections?
Trial Locations
- Locations (1)
Los Angeles County - USC Med Ctr
🇺🇸Los Angeles, California, United States
Los Angeles County - USC Med Ctr🇺🇸Los Angeles, California, United States